Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

    Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells NYX3W2RLS3m2b4TvfIlkyqCjc4PhfS=> MnPRN{Bl[Xm| M2rUO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGSnb4j5cpVkdGWxc3nk[UBidmGub3f1[U1{\W6|aYTpeoUhdW:3c3WgUFEzOTBiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQhdk1w M3vqdFE6Pjd2OUCz
human CCRF-CEM cells NYLLZnNFS3m2b4TvfIlkyqCjc4PhfS=> NV3aSI1XOyCmYYnz NX;FWGx[S3m2b4TvfIlkcXS7IHHnZYlve3RiZHXvfJlvfWOuZX;zbYRmKGGwYXzv[5VmNXOnboPpeIl3\SCqdX3hckBES1KILVPFUUBk\WyuczDh[pRmeiB|IHThfZMh[nliTWTUJIF{e2G7LDDJR|UxRTFibl2u NGTGc2YyQTZ5NEmwNy=>
human MCF7 cells MYjDfZRwfG:6aXRCpIF{e2G7 M1XPR|Mh\GG7cx?= NFrhcHJEgXSxdH;4bYNqfHliYXfhbY5{fCCmZX;4fY52[2ynb4Pp[IUh[W6jbH;neYUue2Wwc3n0bZZmKGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME20JI5ONg>? MYqxPVY4PDlyMx?=
CCRF-CEM cell line MoS3SpVv[3Srb36gZZN{[Xl? MW\Jcohq[mm2IITo[UBz\XCuaXPheIlwdiCxZjDDR3JHNUOHTTDj[YxtKGyrbnWgbY4hfmm2cn:sJGVFPTB;NTDuUU4> MmjRNVk6PTh7NB?=
human P12-ICHIKAWA cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTWTY5pcWKrdHnvckBw\iCqdX3hckBROTJvSVPITWtCX0FiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkW0JI5ONg>? MlzGV2FPT0WU
human CCRF-CEM cells Mn21R5l1d3SxeHnjxsBie3OjeR?= NVfuSoJWPDhiaB?= NEDQflVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBGSzVyPUWuOlEhdk1w MoXrNVk4PDN6NUi=
CCRF-CEM cell lines MnfrSpVv[3Srb36gZZN{[Xl? NULjO41jPzJiaB?= MW\Dc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRicnXwcIlk[XSrb36gc4YhS0OURj3DSW0h[2WubDDsbY5meyCkeTC1NEUh[W[2ZYKgO|IhcHJiaX7jeYJifGmxbjygSWQ2OD14IH7NMi=> NGLnW3IyPjV{MEK0
human CCRF-CEM cells NHjEZWVEgXSxdH;4bYPDqGG|c3H5 NVPBbHYxPDhiaB?= MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDR3JHNUOHTTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2WubITpeIVzNWKudXWgZZN{[XluIFnDOVA:PiCwTT6= NE\CTGgzOjV6Mkm5NS=>
human SF268 cells MYfDfZRwfG:6aXRCpIF{e2G7 MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTSlI3QCClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVA:Py54ODDuUU4> NF\kfJAyQTN2NUW4NS=>
MOLT-4 human leukemic lymphoblastoid cell lines NX24O|NpS3m2b4TvfIlkyqCjc4PhfS=> MULDfZRwfG:6aXPpeJkh[WejaX7zeEBOV0yWLUSgbJVu[W5ibHX1b4VucWNibIntdIhw[myjc4TvbYQh[2WubDDsbY5meyxiSVO1NF0yOCCwTT6= MYO2PFI4PTR4
human 697 cell NYD5bHJwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH7LU2dKdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlYhdk1w M4PhNHNCVkeHUh?=
human ES1 cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlLNTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMj65O{BvVS5? MXXTRW5ITVJ?
CCRF-CEM human leukemic lymphoblastoid cell lines NVjNVoRKS3m2b4TvfIlkyqCjc4PhfS=> NFvwZ5BEgXSxdH;4bYNqfHliYXfhbY5{fCCFQ2LGMWNGVSCqdX3hckBt\XWtZX3pZ{BtgW2yaH;icIF{fG:rZDDj[YxtKGyrbnXzMEBKSzVyPUKwJI5ONg>? M{nMTlY5Ojd3NE[=
P388 murine cell lines Mnu5SpVv[3Srb36gZZN{[Xl? M4flPVczKGh? MmPDWIhmKGOxbYDveY5lKHejczD0[ZN1\WRiaX6geol1em9iZn;yJIFvfGm2dX3vdkBi[3Srdnn0fUg2OCViaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEkh[WejaX7zeEB1cGViUEO4PEBufXKrbnWgZ4VtdCCuaX7ld{Bi\nSncjC3NkBpd3W{czygTWQ2OD1{MDDuUU4> NV;rS2wyOzZ{NUexOC=>
L1210 murine cell lines NGXqeVRHfW6ldHnvckBie3OjeR?= MmT2O|IhcA>? NFHr[HdVcGViY3;tdI92dmRid3HzJJRme3SnZDDpckB3cXS{bzDmc5Ih[W62aYT1cY9zKGGldHn2bZR6MDVyJTDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpMSCjZ3HpcpN1KHSqZTDMNVIyOCCvdYLpcoUh[2WubDDsbY5meyCjZoTldkA4OiCqb4Xyd{whUUR3ME2yNEBvVS5? MnXhN|YzPTdzNB?=
human HEL cell Ml3nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M175U2lvcGmkaYTpc44hd2ZiaIXtZY4hUEWOIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkCuOVIhdk1w MnHHV2FPT0WU
human CCRF-CEM/C2 cells MYTDfZRwfG:6aXRCpIF{e2G7 NUPwd4FVPDhiaB?= NFzLUFJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUU9EOiClZXzsd{Bi\nSncjC0PEBpenNiYomgZ4VtdCC2aYTldk1jdHWnIHHzd4F6NCCHQ{WwQVIzNjhibl2u MX2xPVc1Ozh3OB?=
mouse L1210 cells MWXDfZRwfG:6aXRCpIF{e2G7 NFKzc3o1QCCq MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDMNVIyOCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC0PEBpenNuIFnDOVA:OC5yMkSg{txONg>? NEfrUFgzODByMESxPC=>
human CEM cells MmPtR5l1d3SxeHnjxsBie3OjeR?= M2P1WFQ5KGh? MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDSW0h[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNEigbJJ{NCCLQ{WwQVAvODJ2IN88UU4> MVqyNFAxODRzOB?=
human 2209-23 cells M3\LUHBzd2yrZnXyZZRqd25iYYPzZZk> MnrtRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiB{MkC5MVI{KGOnbHzzJIJ6KFt|SG30bJlucWSrbnWgbY5kd3Kyb4LheIlwdiC|Y3nueIltdGG2aX;uJJBzd3irbXn0fUBie3OjeTygTWM2OD1yLkCyPUDPxE1? M{TTfVE6ODV3NEiy
human CHP-212 cell M{PsPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{PMZmlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM{NjR5IH7NMi=> M{WydHNCVkeHUh?=
human CTB-1 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlrSTY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO0MlMhdk1? M3T4WHNCVkeHUh?=
human A427 cell M4[5OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|ND60PUBvVS5? NWj1eHQ1W0GQR1XS
human MOLT-16 cell NVHnVJViT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOk4xPyCwTT6= NUe1Z3lDW0GQR1XS
human MCF7 1K cells MlfrR5l1d3SxeHnjxsBie3OjeR?= NYm1OYRIOyCmYYnz M{ThOGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGSnb4j5cpVkdGWxc3nk[UBidmGub3f1[U1z\XOrc4ThcpQhcHWvYX6gUWNHPyBzSzDj[YxteyCxdnXy[ZhxemW|c3nu[{BzcWKxboXjcIVwfGmmZTDy[YR2[3Sjc3WgZYZ1\XJiMzDkZZl{KGK7IF3UWEBie3OjeTygTWM2OD12MDDuUU4> MnTVNVk3PzR7MEO=
human MC-IXC cell M1zsNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MofxTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20NU41OSCwTT6= NYD3eIFFW0GQR1XS
human BHT-101 cell NFnTfnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3jGVWlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQyNjd4IH7N NHPFUohUSU6JRWK=
human K5 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmHETY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR|LkKgcm0> Mn;kV2FPT0WU
parent promyelocytic leukemia cell line NYPnXGw{TnWwY4Tpc44h[XO|YYm= MYfBcpRq[2GwY3XyJIFkfGm4aYT5JJdieyCndnHseYF1\WRiZn;yJJRp\SClb33wc5Vv\CCjZ3HpcpN1KHCjcnXueEBxem:veXXsc4N6fGmlIHzleYtmdWmjIHPlcIwhdGmwZTCoTGwuPjBvR1jQVnQsN2SFSzupMEBGTDVyPUS3JI5ONg>? MoT2N|AzPzN{OR?=
human HL60 cells M{\USWN6fG:2b4jpZ:Kh[XO|YYm= MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDj[YxtfGm2ZYKtZox2\SCjc4PhfUwhUUN3ME2wMlA1QSEQvF2u NHeydnkzOjV6Mkm5NS=>
human A549 cell NWW1fXJ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12OT62OkBvVQ>? MVvTRW5ITVJ?
human NCI-H1703 cell Mk\KS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXPSGdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVcxOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR7LkixJI5O MYPTRW5ITVJ?
L1210 cell lines NYfmb5pLTnWwY4Tpc44h[XO|YYm= MV7Dc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRicnXwcIlk[XSrb36gc4YhVDF{MUCgZ4VtdCCuaX7ld{BjgSB3MDWgZYZ1\XJiN{KgbJIhcW6ldXLheIlwdixiRVS1NF0xNjB3IN88UU4> NHT0dHYyPjV{MEK0
human K562 cells MUPDfZRwfG:6aXRCpIF{e2G7 M3Hy[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[nliU2LCJIF{e2G7LDDJR|UxRTBwMEWg{txO MmDSNlQ6PTZ3NU[=
human LB2241-RCC cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPYTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTVwM{Sgcm0> NU\QbIF4W0GQR1XS
human MLMA cell NWf0TnR{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{n5VGlvcGmkaYTpc44hd2ZiaIXtZY4hVUyPQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUW1MlUyKG6P NH7xbXRUSU6JRWK=
human P30-OHK cell MnjaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmrLTY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVYvPSCwTR?= M4OwSHNCVkeHUh?=
RPMI-6410 human leukemic lymphoblastoid cell lines M1XwXGN6fG:2b4jpZ:Kh[XO|YYm= NVTLNGNMS3m2b4TvfIlkcXS7IHHnZYlve3RiUmDNTU03PDFyIHj1cYFvKGyndXvlcYlkKGy7bYDoc4Jt[XO2b3nkJINmdGxibHnu[ZMtKEmFNUC9NE4xPiEQvF2= NGW5fY03QDJ5NUS2
human HT-29 cells M2[1W3Bzd2yrZnXyZZRqd25iYYPzZZk> NXjybYhSSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFY3KM7:TT6= NH;Ke3kzPzd6NES5
human NCI-H510A cell NUXie|lvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWPQOHZ3UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14OD6yOkBvVQ>? MXXTRW5ITVJ?
human J-RT3-T3-5 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHHhWJNKdmirYnn0bY9vKG:oIHj1cYFvKEpvUmSzMXQ{NTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14OD60NkBvVQ>? MUTTRW5ITVJ?
human VA-ES-BJ cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnXoTY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcyNjZ3IH7N NUDkOJN5W0GQR1XS
human T-24 cell M1n0OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVjJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15OD61OkBvVQ>? NXP3[mdlW0GQR1XS
human NB69 cell NFzPc3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15OT60PEBvVQ>? MlP3V2FPT0WU
human BALL-1 cells NWLIOW4{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NULCe3ZtOjRiaB?= M2XQRWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGJCVExvMTDj[YxteyCjZoTldkAzPCCqcoOgZpkhX1OWLUGgZZN{[XluIFfJOVA:OC5yODFOwG0> MofVNlIzPjRzN{C=
HL60 cells NF7o[VdRem:uaX\ldoF1cW:wIHHzd4F6 NUnYcGd3UW5idnn0do8hcW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgdJJwdGmoZYLheIlwdiCxZjDIUFYxKGOnbHzzMEBKSzVyPUCuNFgh|ryP M1TJ[FEzQDd5NUmz
human CTV-1 cell NEjpOotIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWfX[Gp3UW6qaXLpeIlwdiCxZjDoeY1idiCFVG[tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg1Njd2IH7N M133fHNCVkeHUh?=
human MEL-JUSO cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NY\tXW9zUW6qaXLpeIlwdiCxZjDoeY1idiCPRVytTnVUVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTh3Lke2JI5O M2OxOXNCVkeHUh?=
human MOLT-4 cell NFvGVlNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi5MlY4KG6P NGX5WJdUSU6JRWK=
human leukemia cell line(CCRF-CEM) MYDDfZRwfG:6aXRCpIF{e2G7 MXLJckB3cXS{bzDjfZRwfG:6aXPpeJkhd2ZiY3;tdI92dmS|IIfldoUh\GW2ZYLtbY5m\CCxbjDJcohq[mm2aX;uJI9nKGi3bXHuJIxmfWunbXnhJINmdGxibHnu[UhES1KILVPFUUktKEmFNUC9NE4xQSEQvF2u M4Gwd|g6OTd4NEW=
human SW982 cell NEnqZ|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXK1dnVTUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkyNjJ|IH7N MV7TRW5ITVJ?
human NCI-SNU-1 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2fIcmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XoxvJygTWM2OD17Nj63O{BvVQ>? NHXPO5dUSU6JRWK=
HeLa human cell lines NECyO21HfW6ldHnvckBie3OjeR?= MUWxOFQhcA>? NEfmTY1VcGViY3;tdI92dmRid3HzJJRme3SnZDDpckB3cXS{bzDmc5Ih[W62aYT1cY9zKGGldHn2bZR6MDVyJTDpcohq[mm2aX;uJI9nKHS3bX;yJINmdGxiZ4Lve5RpMSCjZ3HpcpN1KEinTHGgbJVu[W5iY3XscEBtcW6nczDh[pRmeiBzNESgbJItKEmGNUC9NE4yKM7:TR?= MX6zOlI2PzF2
human H460 cells NXyxXYY3TnWwY4Tpc44h[XO|YYm= NHjlcVIzPCCq NH;udYxCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYpCpC=> Mlu4NlAzOTF3NkS=
human HCT116 cells MlfJSpVv[3Srb36gZZN{[Xl? M1zVTmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNUDPxE1? MV6yNFIyOTV4NB?=
human GP5d cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;SVJdKdmirYnn0bY9vKG:oIHj1cYFvKEeSNXSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFIhdk1? MUjTRW5ITVJ?
human SAS cell M17C[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmLNTY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEeuOVchdk1? NGTxcIpUSU6JRWK=
human BFTC-905 cell  NELVbW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmTvTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExQC5|MTDuUS=> NXrKSZNvW0GQR1XS
human LB1047-RCC cell MnjIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHXaPIlKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEiuOFIhdk1? M{DVfXNCVkeHUh?=
human BB65-RCC cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYrsd25xUW6qaXLpeIlwdiCxZjDoeY1idiCEQk[1MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzMD6xPUBvVQ>? NUHxNldlW0GQR1XS
human KE-37 cell M1X6NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NI\MWY5KdmirYnn0bY9vKG:oIHj1cYFvKEuHLUO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVExNjh3IH7N M{CzWnNCVkeHUh?=
human NCI-H292 cell M4LXWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEHV[nVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTF2LkKgcm0> MlnIV2FPT0WU
human HT-1080 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17kfGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyPC52NzDuUS=> NWnpdFhnW0GQR1XS
human HL60 cells NGj1[opEgXSxdH;4bYPDqGG|c3H5 MYS0PEBp MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xNVgh|ryP NGXyN5oyQTN{MUKzOC=>
human CAKI-1 cell MmfOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzHdo94fGhiaX7obYJqfGmxbjDv[kBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bi\nSncjCyOEBpenNiYomgW3NVNTFiYYPzZZktKEeLNUC9NE4yOiEQvF2= MXmyNlI3PDF5MB?=
human CAKI-1 cell NXS1fmRGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVXJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGyNEBvVQ>? MVPTRW5ITVJ?
human HMV-II cell M2TnZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M32wb2lvcGmkaYTpc44hd2ZiaIXtZY4hUE2YLVnJJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZk> MYfTRW5ITVJ?
human ES8 cell M1L0eWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWq5NmF3UW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlMvQTNibl2= MWjTRW5ITVJ?
human NEC8 cell MkfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGXscGZKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN|QvOjFibl2= MnWyV2FPT0WU
human EW-1 cell NWXaTmxUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XqZ2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzPE43OiCwTR?= Mn3LV2FPT0WU
murine leukemia P388 MoTvSpVv[3Srb36gZZN{[Xl? MknLRY51cWOjbnPldkBi[3Srdnn0fUBk[XK{aXXkJI92fCCrbjD2bZRzdyCjZ3HpcpN1KG23cnnu[UBt\XWtZX3pZUBROzh6LDDJR|UxRTBwMUSg{txO MXmxNVM2PjFzMB?=
human H-EMC-SS cell NUewSVU3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQ2NjJ6IH7N MUfTRW5ITVJ?
human SNU638 cells NGfxS3BEgXSxdH;4bYPDqGG|c3H5 M{\xfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNPXTZ|ODDj[YxteyCkeTDTVmIh[XO|YYmsJGlEPTB;MD6xOUDPxE1? M2ewbVI1QTV4NUW2
human COR-L105 cell M4HDO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1PMPWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPjBwM{mgcm0> NX\tcZMyW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
+ Expand

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
+ Expand
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03583424 Recruiting Hematopoietic Cell Transplantation Recipient|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) July 9 2018 Phase 1|Phase 2
NCT03519984 Recruiting Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Myelodysplastic/Myeloproliferative Neoplasm|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|T Acute Lymphoblastic Leukemia University of Southern California|National Cancer Institute (NCI)|Vasgene Therapeutics Inc|Whittier Foundation May 9 2018 Phase 1
NCT02403310 Active not recruiting Leukemia|Acute Myeloid Leukemia|AML H. Lee Moffitt Cancer Center and Research Institute|Karyopharm Therapeutics Inc June 9 2015 Phase 1
NCT01921387 Active not recruiting Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) October 9 2013 Phase 1|Phase 2
NCT01476839 Recruiting Recurrent Adult Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) November 9 2012 Phase 1
NCT01190930 Active not recruiting Acute Lymphoblastic Leukemia|Adult B Lymphoblastic Lymphoma|Ann Arbor Stage I B Lymphoblastic Lymphoma|Ann Arbor Stage II B Lymphoblastic Lymphoma|Childhood B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Lymphoblastic Lymphoma|Down Syndrome|Hypodiploid B Acute Lymphoblastic Leukemia|Intrachromosomal Amplification of Chromosome 21|Philadelphia Chromosome Positive|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Children''s Oncology Group|National Cancer Institute (NCI) August 9 2010 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID